source
- Boehringer bets big on China, offering $7B biobucks for Sino cancer programsBoehringer Ingelheim is building up its China strategy, inking a deal to develop new cancer treatments with Sino Biopharmaceutical just weeks after opening an R&D facility in Shanghai.
- Amgen launches autoinjector study for GLP-1 candidate MariTide as Phase 3 readouts loomAmgen has begun a study of an autoinjector formulation of its GLP-1 drug candidate MariTide, as the company prepares for pivotal Phase 3 data expected next year. The candidate is marketed as havin…